Alligator Bioscience AB (LTS:0RK9) Total Operating Expense: kr36.27 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Alligator Bioscience AB Total Operating Expense?

Alligator Bioscience AB LTS:0RK9 -2.35% Total Operating Expense is kr36.27 Mil as of Jun. 2026. The stock has 6 warning signs investors should review.

Alligator Bioscience AB's Total Operating Expense for the three months ended in Jun. 2026 was kr36.27 Mil. Alligator Bioscience AB's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was kr36.27 Mil.

Alligator Bioscience AB Total Operating Expense Related Terms

Alligator Bioscience AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Total Operating Expense Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 153.14 67.41

Alligator Bioscience AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.59 - 0.00 17.58 36.27

Alligator Bioscience AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr36.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr36.27 Mil mean?
Alligator Bioscience AB (LTS:0RK9) has a Total Operating Expense of kr36.27 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Total Operating Expense too high?
Alligator Bioscience AB's current Total Operating Expense is kr36.27 Mil.
How does Alligator Bioscience AB's Total Operating Expense compare to VRTX and REGN?
Alligator Bioscience AB's Total Operating Expense of kr36.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Total Operating Expense is kr36.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (LTS:0RK9) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,050.63, compared to a current price of kr0.02 — trading 100% below its estimated fair value. The current Total Operating Expense is kr36.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Alligator Bioscience AB (LTS:0RK9), the current Total Operating Expense is kr36.27 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a Swedish clinical-stage biotechnology company focused on developing antibody-based immunotherapies for cancer. Its lead candidate, mitazalimab, is a CD40 agonist antibody being developed for metastatic pancreatic cancer and other tumor types. The pipeline also includes bispecific antibody programs such as ATOR-4066, which targets CD40 and CEACAM5, along with partnered assets developed with external collaborators. The company's approach centers on activating the immune system through CD40 and related pathways to enhance anti-tumor responses. As a clinical-stage company, Alligator generates limited product revenue and funds operations primarily through licensing agreements, research collaborations, and equity financings rather than commercial drug sales. Its activities are based in Sweden, with partnerships and clinical trials extending internationally.